Notice of Sunshine Act Meeting, 5849-5850 [2012-2635]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 24 / Monday, February 6, 2012 / Notices
Dated: January 27, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
[FR Doc. 2012–2591 Filed 2–3–12; 8:45 am]
By Notice dated September 28, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62449,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Gamma
Hydroxybutyric
Acid
(GHB) (2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Phenylacetone (8501) ..................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium raw (9600) ........................
Oxymorphone (9652) ...................
Poppy Straw Concentrate (9670)
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company will manufacture the
listed controlled substances in bulk for
sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 USC § 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
VerDate Mar<15>2010
17:27 Feb 03, 2012
Jkt 226001
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 28, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62450, GE
Healthcare, 3350 North Ridge Avenue,
Arlington Heights, Illinois 60004–1412,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease, and to manufacture
a bulk investigational new drug (IND)
for clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of GE
Healthcare to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated GE
Healthcare to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–2586 Filed 2–3–12; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
5849
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 23, 2011, and
published in the Federal Register on
July 5, 2011, 76 FR 39127, Johnson
Matthey Pharmaceutical Materials, Inc.,
Pharmaceuticals Service, 25 Patton
Road, Devens, Massachusetts 01434,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Remifentanil (9739), the basic class of
controlled substance in schedule II.
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substance in
bulk and to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey. The controlled substances
manufactured in bulk at this facility will
be distributed to the company’s
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Pharmaceutical
Materials, Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Johnson
Matthey Pharmaceutical Materials, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: January 27, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–2568 Filed 2–3–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Parole Commission
Notice of Sunshine Act Meeting
11:30 a.m., Thursday,
February 9, 2012.
TIME AND DATE:
Frm 00095
Fmt 4703
Sfmt 4703
E:\FR\FM\06FEN1.SGM
06FEN1
5850
Federal Register / Vol. 77, No. 24 / Monday, February 6, 2012 / Notices
U.S. Parole Commission, 90 K
Street NE., 3rd Floor, Washington, DC.
STATUS: Closed.
MATTERS TO BE CONSIDERED:
Determination on one original
jurisdiction case.
PLACE:
CONTACT PERSON FOR MORE INFORMATION:
Patricia W. Moore, Staff Assistant to the
Chairman, U.S. Parole Commission, 90
K Street NE., 3rd Floor, Washington, DC
20530, (202) 346–7001.
Dated: January 31, 2012.
Rockne Chickinell,
General Counsel, U.S. Parole Commission.
[FR Doc. 2012–2635 Filed 2–2–12; 4:15 pm]
BILLING CODE 4410–31–P
DEPARTMENT OF JUSTICE
Parole Commission
Notice of Sunshine Act Meeting
10 a.m., Thursday,
February 9, 2012.
PLACE: U.S. Parole Commission, 90 K
Street NE., 3rd Floor, Washington, DC.
STATUS: Open.
MATTERS TO BE CONSIDERED: Approval of
December 8, 2011 minutes; reports from
the Chairman, the Commissioners, and
senior staff; Mental Health Docket.
CONTACT PERSON FOR MORE INFORMATION:
Patricia W. Moore, Staff Assistant to the
Chairman, U.S. Parole Commission, 90
K Street NE., 3rd Floor, Washington, DC
20530, (202) 346–7001.
TIME AND DATE:
Dated: January 31, 2012.
Rockne Chickinell,
General Counsel, U.S. Parole Commission.
[FR Doc. 2012–2637 Filed 2–2–12; 4:15 pm]
BILLING CODE 4410–31–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Notice of Random Assignment Study
To Evaluate Workforce Investment Act
Adult and Dislocated Worker
Programs; Final Notice
Employment and Training
Administration (ETA), Labor.
ACTION: Notice.
mstockstill on DSK4VPTVN1PROD with NOTICES
AGENCY:
The Employment and
Training Administration (ETA) of the
Department of Labor (DOL or the
Department) will conduct an evaluation
to provide rigorous, nationallyrepresentative estimates of the net
impacts of intensive services and
training provided under the Workforce
SUMMARY:
VerDate Mar<15>2010
17:27 Feb 03, 2012
Jkt 226001
Investment Act (WIA) Adult and
Dislocated Worker Programs. The
Department has determined that it is in
the public interest to use a random
assignment impact methodology for the
study. This methodology will provide
ETA with estimates of the net impacts
of WIA intensive services and training
that are offered during the evaluation
study period. On July 21, 2011 (76 FR
43729–43731), the Department solicited
comments concerning the Department’s
plan to use random assignment
methodology in carrying out the study.
This notice is to provide the
Department’s response to the comments
received.
FOR FURTHER INFORMATION CONTACT:
Eileen Pederson, U.S. Department of
Labor, Employment and Training
Administration, Office of Policy
Development and Research, 200
Constitution Avenue NW., Frances
Perkins Bldg., Room N–5641,
Washington, DC, 20210. Telephone:
(202) 693–3647 (this is not a toll-free
number) or email:
pederson.eileen@dol.gov. Individuals
with hearing or speech impairments
may access the telephone number above
via TTY by calling the toll-free Federal
Information Relay Service at 1–(877)
889–5627 (TTY/TDD).
SUPPLEMENTARY INFORMATION:
I. Background
On July 21, 2011, the Department
announced its plans to conduct an
evaluation of the net impacts of
intensive services and training provided
under WIA (Pub. L. 105–220) Adult and
Dislocated Worker Programs. To obtain
rigorous, nationally representative
estimates of WIA’s effectiveness for
adults and dislocated workers, the
Department determined that it would
use random assignment impact
methodology for the evaluation.
The design of the study was described
as follows: The evaluation will be done
in approximately 30 randomly selected
LWIAs. WIA applicants in the selected
LWIAs who are eligible for intensive
services would be randomly assigned to
one of three groups. The three research
groups to which they would be assigned
are: (1) The full-WIA group—adults and
dislocated workers in this group can
receive any WIA services and training
for which they are eligible, (2) the coreand-intensive group—adults and
dislocated workers in this group can
receive any WIA services for which they
are eligible but no training, and (3) the
core-only group—adults and dislocated
workers in this group can receive only
WIA core services but no intensive
services or training.
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
In the LWIAs selected for the study,
all applicants for intensive services and/
or training will be asked to participate
in the study during the 12–18 month
study enrollment period. They will be
informed of the evaluation, provided an
opportunity to ask questions or seek
clarification of their role and
responsibilities should they agree to
participate, and then required to give
their consent to participate. Applicants
who do not consent to participate in the
study will not be randomly assigned to
one of the study groups but will be
allowed to receive core services only.
The participant enrollment period will
range between 12 and 18 months in
each LWIA.
To protect the rights and welfare of
WIA program applicants who agree to
participate in the evaluation, the
evaluation team, led by researchers from
Mathematica and its subcontractor
MDRC, submitted the WIA Adult and
Dislocated Worker Programs evaluation
design to MDRC’s Institutional Review
Board (IRB) for concurrence. An IRB is
a committee specifically responsible for
protecting the rights and welfare of
humans involved in biomedical and
behavioral research. On June 17, 2010,
MDRC’s IRB determined this study to be
of no more than minimal risk and
approved it.
The Department requested comments
concerning its intent to carry out the
random assignment study described
above. The Department asked for
comments focused on whether there is
a methodology that would yield as
credible and reliable impacts of the WIA
programs as random assignment, but
avoids adverse effect on the study
participants. The Department also
welcomed comments that suggest ways
to more effectively minimize any
adverse impact on the study
participants who participate in the
study described above.
II. Discussion of Comments Received
The Department received comments
from four sources in response to the
notice. The comments were received
from two workforce departments, one
advocacy group, and one private citizen.
The Department’s responses to the
comments are provided below.
Comment: Two commenters asked
about how other sources of funding for
services would be accounted for in the
study. One of these commenters asked
whether the core-only group would
have access to other partner services
and, if so, the commenter suggested that
the study take it into account through
the follow-up survey. The other
commenter was concerned that the
study would not capture the nature of
E:\FR\FM\06FEN1.SGM
06FEN1
]]>Agencies
[Federal Register Volume 77, Number 24 (Monday, February 6, 2012)]
[Notices]
[Pages 5849-5850]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-2635]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Parole Commission
Notice of Sunshine Act Meeting
TIME AND DATE: 11:30 a.m., Thursday, February 9, 2012.
[[Page 5850]]
PLACE: U.S. Parole Commission, 90 K Street NE., 3rd Floor, Washington,
DC.
STATUS: Closed.
MATTERS TO BE CONSIDERED: Determination on one original jurisdiction
case.
CONTACT PERSON FOR MORE INFORMATION: Patricia W. Moore, Staff Assistant
to the Chairman, U.S. Parole Commission, 90 K Street NE., 3rd Floor,
Washington, DC 20530, (202) 346-7001.
Dated: January 31, 2012.
Rockne Chickinell,
General Counsel, U.S. Parole Commission.
[FR Doc. 2012-2635 Filed 2-2-12; 4:15 pm]
BILLING CODE 4410-31-P
